BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BioCentury | Jan 24, 2020
Finance

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year. Created in 2017 by former Merck KGaA...
BioCentury | Jan 12, 2020
Emerging Company Profile

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

Alexis Borisy has launched EQRx to disrupt the biopharma world by developing and launching innovative therapies at “radically lower” prices than commercial competitors. With its first drug expected to hit the market in five years,...
BC Extra | Oct 28, 2019
Clinical News

TG makes case for umbralisib as safer lymphoma option

Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial. TG Therapeutics...
BC Extra | Sep 26, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BC Extra | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team...
BC Extra | Jun 20, 2019
Company News

Management tracks: Verastem CEO Forrester steps down; plus Recursion, N8 Medical

Verastem Inc. (NASDAQ:VSTM) said Robert Forrester will step down as president and CEO. COO Dan Paterson will succeed Forrester as president and lead the executive team while the board searches for a permanent successor. The...
BC Extra | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
BC Extra | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
Items per page:
1 - 10 of 148
BioCentury | May 16, 2020
Management Tracks

Management Tracks: Evox, Phoenix Tissue Repair, Artax, Nucleix, IsoPlexis, Centogene, Immunicum, CohBar and CorMedix

Evox Therapeutics Ltd. said Paul Carter will succeed Edwin Moses as non-executive chairman. Carter was EVP, chief commercial officer of Gilead Sciences Inc. (NASDAQ:GILD). The exosome therapeutics company partnered with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502;...
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BioCentury | Jan 24, 2020
Finance

iOnctura taps European syndicate for series A to bring two ‘best-in-class’ programs to the clinic

On the strength of its new €15 million ($16.6 million) series A round, iOnctura believes it can have two best-in-class oncology candidates in the clinic within a year. Created in 2017 by former Merck KGaA...
BioCentury | Jan 12, 2020
Emerging Company Profile

Borisy newco aims to offer ‘radically’ cheaper drugs by disrupting biopharma’s traditional model

Alexis Borisy has launched EQRx to disrupt the biopharma world by developing and launching innovative therapies at “radically lower” prices than commercial competitors. With its first drug expected to hit the market in five years,...
BC Extra | Oct 28, 2019
Clinical News

TG makes case for umbralisib as safer lymphoma option

Bolstering support for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib met the primary endpoint in a second lymphoma indication in the Phase IIb UNITY-NHL trial. TG Therapeutics...
BC Extra | Sep 26, 2019
Company News

Management tracks: Neurogene, HomoShear, Hookipa, Passage Bio, Artios, EMD Serono, Novartis, Illumina, Precision and CureDuchenne

Neurogene Inc . hired Christine Mikail as president. She is a co-founder of neurology specialty pharma Neumentum Inc. and biotech consulting firm Ferndale Advisors. Neurogene is developing disease-modifying gene therapies for two monogenic, pediatric disorders in...
BC Extra | Jul 29, 2019
Company News

July 29 Management tracks: Verastem names CEO; plus Zealand, Turning Point, Arvinas and more

Verastem Inc. (NASDAQ:VSTM) named board member Brian Stuglik as CEO. In June, Robert Forrester stepped down as the cancer company's president and CEO; COO Dan Paterson succeeded Forrester as president and led the executive team...
BC Extra | Jun 20, 2019
Company News

Management tracks: Verastem CEO Forrester steps down; plus Recursion, N8 Medical

Verastem Inc. (NASDAQ:VSTM) said Robert Forrester will step down as president and CEO. COO Dan Paterson will succeed Forrester as president and lead the executive team while the board searches for a permanent successor. The...
BC Extra | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
BC Extra | May 31, 2019
Company News

Vigeo debuts to reprogram tumor microenvironment

Vigeo emerged from stealth Friday with $27.5 million from Morningside Venture Capital and a cancer candidate already in the clinic. Vigeo Therapeutics Inc. (Cambridge, Mass.) is developing a pipeline of peptides, fusion proteins and antibodies...
Items per page:
1 - 10 of 148